Articles related to TARGETED THERAPIES

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.

As we navigate this new era of oncology care, it’s important to remember that only 38% of studies combining chemotherapy with a targeted treatment administered both drugs at full dose. This underscores the need for careful dose adjustments when combining different classes of drugs.

As we embrace the era of antibody-drug conjugates (ADCs) in cancer therapy, it’s crucial to understand their impact on ocular health. With ADCs like mirvetuximab offering new hope for ovarian cancer patients, effective partnerships between optometrists and oncologists are key to managing associated ocular adverse events.

Explore the intricate relationship between stem cell self-renewal and precancer states to better understand its implications for future cancer therapies

Discover how mechanoresilient cancer cells evade the body’s natural defenses and what this means for the future of targeted cancer therapies.